Trial Profile
Phase II study of Vaccination with Epitope peptides in combiNation with gemcitabine for UnreSectable Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs OCV C01 (Primary) ; Gemcitabine
- Indications Ductal carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms VENUS-PC
- 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record (Parent trial: UMIN000008082).
- 06 Jun 2012 New trial record